Where Will Eli Lilly Be in 10 Years? 1 Clue: Its Next Potential Blockbuster Just Beat Ozempic Head-to-Head
The past decade has been eventful for Eli Lilly (LLY +0.05%). The company made significant breakthroughs in diabetes and weight loss, which helped drive its market value to over $1 trillion, making it the first healthcare stock to achieve that milestone. Eli Lilly's biggest growth drivers are currently Mounjaro for diabetes and Zepbound for weight management, which share the same active ingredient, tirzepatide.
Over the next five years, the pharmaceutical leader could earn approval for important brand-new drugs that will help send its sales even higher. And one of the company's candidates, retatrutide, recently posted excellent results in yet another clinical trial. Let's discuss what all that means for Eli Lilly's long-term prospects.
Image source: Getty Images.
Eli Lilly scores another win against its biggest competitor
According to some estimates, the GLP-1 market could be valued at $190 billion by 2035, up from just $79 billion in 2025. Several factors will help propel this area much higher, including the fact that GLP-1 medicines may expand their reach across various therapeutic areas. Tirzepatide is a good test case here.
Not only is it approved for diabetes and weight management, but it has also earned an indication for obstructive sleep apnea. Further, in recent months, it has shown strong results as a combination treatment -- along with the immunosuppressant Taltz -- for certain autoimmune conditions, including plaque psoriasis. That's a key reason tirzepatide could generate about $62 billion in revenue by 2030, according to some estimates.
Competition will intensify, but Eli Lilly's pipeline could help it fend off other pharmaceutical giants. Consider that retatrutide recently completed a Phase 3 clinical trial in which it was pitted against Ozempic, a diabetes medicine marketed by Lilly's biggest competitor, Novo Nordisk (NVO +0.12%).
Retatrutide posted much higher A1C reductions and weight loss than the highest approved Ozempic dose. This is a meaningful win that could help improve Eli Lilly's long-term competitive position against the only company that has so far posed a serious threat. And the best part: There are more attractive candidates in the pipeline. Consider Eli Lilly's eloralintide.
This medicine mimics the amylin hormone, and it has shown highly promising results as a combo treatment, along with tirzepatide, in patients with type 2 diabetes and obesity. That's another product that could help Eli Lilly expand the market. There is also Foundayo, which could be particularly important for the pharmaceutical leader's global plans.
Foundayo is an oral GLP-1 medicine indicated for weight loss, but it is targeting additional approvals across diabetes, sleep apnea, hypertension, and more. Foundayo is likely cheaper to manufacture at scale than injectable medicines, more convenient for many patients, and may allow Eli Lilly to reach many more patients in developing countries, which is one of its long-term goals.
Most people with diabetes live in these regions, making this a massive opportunity for the company.
Another decade of excellence
Given Eli Lilly's strong lineup and pipeline, there is a good chance that in 10 years, it will remain one of the leaders in its core therapeutic areas. But can the stock beat broader equities over the long run? In my view, it can. Not only is the company making excellent clinical and commercial progress in its core area, but its work in oncology, immunology, and neuroscience should also gradually improve its financial results.
For instance, in oncology, the company's Jaypirca recorded $228 million in revenue in the third quarter, growing 59% year over year, and this medicine is undergoing several clinical trials that could lead to label expansions. It was only approved in 2023, so it has years of growth ahead. Kisunla, a medicine for Alzheimer's disease, is also posting excellent sales growth while targeting various label expansions. These are only the tip of the iceberg.
Eli Lilly has a deep pipeline beyond GLP-1 products that could support strong sales and earnings growth over the long term and allow the company to deliver above-average returns once again. The stock could be significantly up from current levels in a decade. It is worth investing in Eli Lilly right now.
-- Price
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
You may also like

These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys

4 Chip Stocks Down as Much as 36% From Their Highs to Buy and Hold for the Next Decade

Strategy planned to slow STRC buybacks near $100 but spent another $1.4 billion instead

Michael Burry Cashed In Caterpillar Puts After a Nearly 4x Gain Even as CAT Stock Fell 10% in Its Worst Week in 18 Months. Is Caterpillar Still Overvalued, or Did Burry Just Lock In the Easy Money?

XRP’s proposed upgrade could improve trading without boosting token demand

Clarity Act Defeat ‘Failure of American Leadership’: Trump’s Former Crypto Chief

Plug Power Reports Q3 Results, Cash Declines to 134 Million Dollars, Operating Loss of 75.2 Million Dollars

3 Financial Stocks to Buy and Hold That Turned $1,000 Into More Than $5,000 Over the Past Decade, Counting Dividends

'Tokenization Is Not the Finish Line': Jupiter to Let Users Borrow Against Bullish Shares

Anthropic's Wall Street Operator: CFO Krišna Rao

'Nobody Knows Who's in Charge': Boris Johnson Stands by Bitcoin Skepticism at Breakpoint

Mazama Energy Finds New Solution to the Biggest Challenge in Geothermal Drilling

Have Semiconductors Bottomed? Here's How the Current Chip Stock Plunge Compares With Past Bear Markets.

Is Apple Losing Its Memory?

Rising Transportation Costs Make Large Holiday Purchases More Difficult

Zhao Changpeng Lists Six Possible Reasons for Bitcoin's Decline: Anthropic IPO and ETF Redemptions, Security Incidents, Regulatory Uncertainty, and More

J.P. Morgan's Forecast for 2027: Inflation Around 2% and Increased Pressure on the Dollar

The Amber Controversy: Diverging Paths with Wintermute

First Financial Report After Jensen Huang's Departure: Colette Kress Faces Core Questions

Dreamteam Completes $53 Million Financing to Expand AI CRM Business

Stellar Bell Vote on November 23: What It Means for XLM Holders

Solana Breakpoint attendees warned of robberies after reported wallet theft

Federal Reserve Governor Barr Warns AI Agents May Exacerbate Bank Runs

Trezor found implants in reseller wallets. What protects the buyer?

The Vast Used Car Market: CarMax and Carvana Clash Over Americans' Car Buying Methods

Trump and Xi Jinping to Meet in Shenzhen, Focusing on Chip Regulation and AI Security

Why is the only spot Bitcoin ETF in continental Europe acquired by an Asian group, BIT?

The Application is Landing, Wealth is Evaporating: Analyzing the Painful Roots of the Crypto Industry through Three Financial Statements

A Look at Traditional Banks Entering Web3: Who Made Money and Who Lost?













